Boston Scientific (NYSE:BSX) Releases Quarterly Earnings Results, Meets Expectations

Boston Scientific (NYSE:BSX) posted its quarterly earnings data on Wednesday. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.73, FiscalAI reports. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.07 billion. During the same period in the prior year, the business posted $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 1.4% on a year-over-year basis.

Here are the key takeaways from Boston Scientific’s conference call:

• Q3 missed expectations: Organic revenue grew 1.5%, below the 3%–5% outlook, while adjusted EPS fell 3% to $0.73. The cybersecurity incident reduced revenue growth by roughly 300 basis points and EPS by approximately $0.07.
• Boston Scientific expects continued near-term pressure, guiding to a 1%–3% organic revenue decline and adjusted EPS of $0.77–$0.79 in Q4. Management said 2027 revenue and EPS growth will be challenging as EP and WATCHMAN face market-share and competitive pressures, while China pricing headwinds intensify.
• WATCHMAN sales declined 6% and EP sales declined 5% in Q3, with further EP share erosion expected until new products launch. The company also cited weaker urology performance, China-related pricing pressure, supply constraints, and delays affecting parts of its product pipeline.
• Management expects a return to stronger performance in 2028, supported by launches including FARAWAVE Ultra, 2D ICE, CRM’s Denali platform, new IVL and imaging technologies, and a potential Penumbra contribution. The company identified approximately $25 billion of new market opportunities by 2030.
• A company-wide restructuring program is expected to generate more than $500 million in savings over three years, with over half anticipated by the end of 2027. Boston Scientific said the program should improve operating leverage while preserving investment in key growth platforms.

Boston Scientific Stock Up 0.2%

Boston Scientific stock opened at $42.52 on Thursday. The company has a market capitalization of $61.63 billion, a PE ratio of 17.22, a PEG ratio of 1.10 and a beta of 0.58. Boston Scientific has a 12-month low of $39.57 and a 12-month high of $105.65. The firm’s fifty day moving average is $45.12 and its 200 day moving average is $57.43. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported third-quarter revenue of $5.138 billion, ahead of the $5.07 billion consensus estimate, while adjusted EPS of $0.73 matched expectations. Revenue increased approximately 1.5% year over year. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Management reiterated its long-term growth strategy, including a potential recovery cycle toward 2027 and expansion through 2030. The company also reported progress on the Elite AF clinical trial and new FDA clearances. Boston Scientific Overshadowed by Hackers, Headwinds, and Lower Guidance
• Positive Sentiment: Several analysts still see upside: Robert W. Baird raised its price target to $51 and maintained an “outperform” rating, while BTIG and Needham retained “buy” ratings despite lowering their targets. Recent insider activity also showed purchases by executives.
• Neutral Sentiment: Analyst sentiment has become more cautious. Oppenheimer downgraded BSX to “market perform,” and JPMorgan cut its rating to “neutral” with a $46 price target, reflecting increased near-term uncertainty.
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by approximately $150 million and continues to affect operations, customer activity and the pace of recovery.
• Negative Sentiment: Boston Scientific lowered its full-year 2026 outlook to roughly 4.25% reported sales growth and adjusted EPS of $3.16–$3.18. Fourth-quarter adjusted EPS guidance of $0.77–$0.79 fell short of expectations, while sales are expected to decline 1%–3% year over year. Boston Scientific Crashes As Cybersecurity Attack Weighs On Guide
• Negative Sentiment: Investors are also concerned about contracting margins, weaker heart-device demand and challenging pricing conditions in China, which management indicated could make 2027 difficult.

Insiders Place Their Bets

In related news, CEO Michael Mahoney purchased 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward Ludwig acquired 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by company insiders.

Analyst Ratings Changes

BSX has been the topic of a number of recent analyst reports. Sanford C. Bernstein restated an “outperform” rating and issued a $54.00 price target (down from $60.00) on shares of Boston Scientific in a research report on Saturday, October 3rd. BTIG Research decreased their price objective on shares of Boston Scientific from $56.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday. Wells Fargo & Company lowered their target price on shares of Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating for the company in a research note on Wednesday, September 23rd. Canaccord Genuity Group set a $48.00 target price on shares of Boston Scientific in a report on Thursday. Finally, Barclays raised shares of Boston Scientific to a “hold” rating in a research report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $63.60.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.